panel action like mean merck begin
sell new drug call proscar sometim later
year mani doctor treat urolog problem believ
proscar gain wide use would first approv
medicin avail treat condit call benign
prostat hypertrophi bph affect 15 million
men u.
secur analyst predict drug becom
merck next big money maker perhap generat world-wid
sale $ 500 million $ 1 billion 1995
panel recommend expect came
end trade new york stock exchang
anticip panel final rule merck share
rose $ 4.50 close $ 158.875 analyst meet
bethesda md. react data drug
day-long public hear
rahway n.j. compani studi show drug
also known finasterid produc signific symptom
relief taken daili tablet 31 % men given
drug compar 18 % relief rate report men
receiv placebo dummi pill
75 % men age 50 experi varieti
pain annoy problem urinari tract
block grow prostat proscar first drug
design shrink gland current 400,000
american men year annual cost $ 3 billion
undergo surgeri reliev block urin flow
condit becom serious
merck expect mani patient opt proscar
instead although studi found everi patient
benefit drug signific relief often take
three six month patient also need stay drug
keep problem return
inde analyst expect merck face stiff
market battl convinc doctor use
drug alreadi mani doctor treat bph blood
pressur drug call hytrin sold abbott laboratori
abbott park ill. sinc 1987. late decemb abbott ask
fda allow compani market hytrin treat
bph clinic trial hytrin increas urin flow 41 %
hytrin appar advantag provid relief
immedi although effect size
prostat hytrin appear relax muscl surround
block urinari tract major studi compar two drug
well test use togeth expect get
way soon
expect lot men go give drug tri
mean avoid surgeri said mark solloway chairman
depart urolog univers miami
school medicin want instant relief re go
tri hytrin mani men use proscar hope keep
problem get wors especi sinc proscar
virtual side-effect free
market fight bph intensifi analyst
said pfizer inc. also seek sell drug
similar hytrin smithklin beecham plc develop
one much like proscar
proscar success realli depend receiv
get market said mark mayer analyst
sanford c. bernstein co. merck shown us
past good persuad doctor tri
total new kind drug
analyst expect proscar join two
huge-sel drug help drive merck earn
next year current merck high-blood pressur
drug vasotec cholesterol-low drug mevacor
generat world-wid revenu $ 1 billion
